Journal article · 2025 · Open access
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
New England Journal of Medicine, 393(24), 2409–2420 · Published 17 December 2025 · DOI 10.1056/nejmoa2505928
In brief
“Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes” is a 2025 journal article by Stephen James Nicholls and 26 co-authors, published in New England Journal of Medicine. OpenAlex counts 285 citations as of 16 November 2026. It is open access: the full text is free to read at SZTE Publicatio Repozitórium (University of Szeged).
- Citations
- 285
- Most cited in
- 2026 (281)
- Field-weighted impact
- 142.40
- References
- 31
- Authors
- 27
Abstract
BACKGROUND: Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on glycemic control and body weight. The effects on cardiovascular outcomes are uncertain. METHODS: We conducted an active-comparator-controlled, double-blind, noninferiority trial in which patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomly assigned in a 1:1 ratio to receive a weekly subcutaneous injection of tirzepatide (up to 15 mg) or dulaglutide (1.5 mg), an agent that has been shown to reduce the incidence of cardiovascular events. The primary end point was a composite of death from cardiovascular causes, myocardial infarction, or stroke and was tested for noninferiority of tirzepatide to dulaglutide with a margin of 1.05 for the upper limit of the 95.3% confidence interval for the hazard ratio. An upper limit of less than 1.00 was considered to indicate superiority of tirzepatide to dulaglutide. RESULTS: A total of 13,299 patients underwent randomization; 134 were subsequently excluded because they did not meet inclusion criteria. The modified intention-to-treat population thus included 6586 patients in the tirzepatide group and 6579 in the dulaglutide group. The mean (±SD) age of the patients was 64.1±8.8 years, 29.0% were women, the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 32.6±5.5, the mean glycated hemoglobin level was 8.4±0.9%, and the mean duration of diabetes was 14.7±8.8 years. A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01; P = 0.003 for noninferiority; P = 0.09 for superiority). The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction, or stroke. (Funded by Eli Lilly; SURPASS-CVOT ClinicalTrials.gov number, NCT04255433.).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Nicholls, S. J., Pavo, I. J., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D. L., Nauck, M. A., Nishiyama, H., Nissen, S. E., Sattar, N. A., Weerakkody, G. J., Wiese, R. J., Zinman, B., Zoungas, S., Basile, J., Davies, M. J., . . . D’Alessio, D. A. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 393(24), 2409–2420. https://doi.org/10.1056/nejmoa2505928
MLA 9
Nicholls, Stephen James, et al. “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.” New England Journal of Medicine, vol. 393, no. 24, 2025, pp. 2409–2420. https://doi.org/10.1056/nejmoa2505928.
Chicago
Nicholls, Stephen James, Imre J. Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, Abraham Michael Lincoff, et al. 2025. “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.” New England Journal of Medicine 393 (24): 2409–2420. https://doi.org/10.1056/nejmoa2505928.
Harvard
Nicholls, S. J. et al. (2025) ‘Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes’, New England Journal of Medicine, 393(24), pp. 2409–2420. doi:10.1056/nejmoa2505928.
IEEE
S. J. Nicholls et al., “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes,” New England Journal of Medicine, vol. 393, no. 24, pp. 2409–2420, 2025, doi: 10.1056/nejmoa2505928.
BibTeX
@article{nicholls2025cardiovascular,
title = {{Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes}},
author = {Nicholls, Stephen James and Pavo, Imre J. and Bhatt, Deepak L. and Buse, John B. and Del Prato, Stefano and Kahn, Steven E. and Lincoff, Abraham Michael and McGuire, Darren K. and Miller, Debra Lee and Nauck, Michael Albrecht and Nishiyama, Hiroshi and Nissen, Steven E. and Sattar, Naveed A. and Weerakkody, Govinda J. and Wiese, Russell J. and Zinman, Bernard and Zoungas, Sophia and Basile, Jan and Davies, Melanie J and Giorgino, Francesco and Kellerer, Monika and Ji, Linong and Várkonyi, Tamás T. and Menon, Venu and Broder, Jonathan C. and Herschtal, Alan and D’Alessio, David A.},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {24},
pages = {2409--2420},
doi = {10.1056/nejmoa2505928},
url = {https://doi.org/10.1056/nejmoa2505928}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 1 | |
| 2020 | 1 | |
| 2024 | 1 | |
| 2025 | 1 | |
| 2026 | 281 |
Its field-weighted citation impact is 142.40: it has been cited 142.40 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- tirzepatide
- dulaglutide
- type 2 diabetes
- cardiovascular outcomes
- non-inferiority
- atherosclerotic cardiovascular disease
- GLP-1 receptor agonists
- GIP receptor agonist
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Nicholls, S. J., Pavo, I. J., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D. L., Nauck, M. A., Nishiyama, H., Nissen, S. E., Sattar, N. A., Weerakkody, G. J., Wiese, R. J., Zinman, B., Zoungas, S., Basile, J., Davies, M. J., . . . D’Alessio, D. A. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 393(24), 2409–2420. https://doi.org/10.1056/nejmoa2505928
How many times has this paper been cited?
285 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at SZTE Publicatio Repozitórium (University of Szeged): sign in and open the PDF from this page.
Who wrote this paper?
Stephen James Nicholls, Imre J. Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, Abraham Michael Lincoff, Darren K. McGuire, Debra Lee Miller, Michael Albrecht Nauck, Hiroshi Nishiyama, Steven E. Nissen and 15 more.
What is the DOI of this paper?
10.1056/nejmoa2505928, permanently at https://doi.org/10.1056/nejmoa2505928. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.